Here is the problem with the MM study. We agreed to a primary endpoint that was impossible to meet. Now we have amazing secondary endpoint data which we blew away. But all that the shorts will focus on is "cydy fails to meet primary endpoint in Covid trial". NP knows this and this is why they are trying to make the results seem as robust as they are. We did screw ourselves. Gilead gave themselves an out by making their primary endpoint flexible and changeable (which they did!). We just agree to all fda demand bc we have no other choice.